Nxera Pharma Co., Ltd.

4565

JP3431300007

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 28/06/2024 am IST			5-day change	1st Jan Change
1,603 ^JPY	-0.56%		+6.37%	+12.81%

27/06	Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	MT
27/06	Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	CI

Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone

June 27, 2024 at 04:35 am IST

Nxera Pharma Co. Ltd. announced that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of USD 10 million to Nxera. Nxera and AbbVie entered into this multi-target collaboration in 2022 to leverage Nxera's NxWave platform to discover, develop and commercialize new medicines targeting novel G protein-coupled receptor (GPCR) targets associated with neurological disease.

Under the terms of the agreement, Nxera is eligible to receive up to USD 40 million in near-term research milestones, as well as further potential option, development and commercial milestones totaling up to USD 1.2 billion, plus tiered royalties on global sales.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	NXERA PHARMA CO., LTD.	1,603 JPY	-0.56%	+6.37%	896M
	ABBVIE INC.	171.5 USD	+1.50%	+0.66%	303B

Latest news about Nxera Pharma Co., Ltd.

Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	27/06	MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	27/06	CI
Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals	31/05	MT
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	30/05	CI
Nxera Pharma Co., Ltd. and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area	30/05	CI
Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	18/04	MT
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	17/04	MT
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16/04	CI
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	16/04	MT
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	15/04	CI
Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC	03/04	CI
Sosei Group Corporation will Change its Name to Nxera Pharma Co., Ltd	01/04	CI
Sosei Shareholders Greenlight Name Change, Top Management Appointments	28/03	MT
Transcript : Sosei Group Corporation - Shareholder/Analyst Call	27/03
Sosei Heptares Begins Phase 1 Trial for Novel Inflammatory Bowel Disease Treatment	22/03	MT
Sosei Group Corporation Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	21/03	CI
Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease	21/03	CI
Jefferies Adjusts Sosei Group’s Price Target to 2,100 Yen From 1,800 Yen, Keeps at Buy	12/03	MT
Sosei Group, Boehringer Ingelheim Enter Into License Deal for Schizophrenia Symptoms	12/03	MT
Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-In-Class Treatments Targeting All Symptoms of Schizophrenia	11/03	CI
Boehringer Ingelheim and Sosei Group Corporation Enter Exclusive Option-To- License Agreement	11/03	CI
Japanese Shares Close Lower But Hit Fresh 52-Week High on US Rate Cut Assurance	07/03	MT
Sosei Group to Get $2.5 Million Milestone Payment from Formosa Pharmaceuticals	07/03	MT
Sosei Group Corporation to Receive $2.5 Million Payment from Formosa Pharmaceuticals	06/03	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	27/02	RE

Chart Nxera Pharma Co., Ltd.

Duration

Period

More charts

Company Profile

Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Nxera Pharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,603 JPY

Average target price

2,111 JPY

Spread / Average Target

+31.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
NXERA PHARMA CO., LTD.	+12.81%	896M
CSL LIMITED	+2.99%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	37.55B
BIOGEN INC.	-10.41%	33.75B
UCB	+75.79%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.61%	15.63B
INCYTE CORPORATION	-3.46%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.31%	11.5B
ALTEOGEN INC.	+184.77%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.13%	9.23B

Biopharmaceuticals